Bahlis, N. J., Usmani, S. Z., Facon, T., Zweegman, S., Venner, C. P., Braunstein, M. J., Pour, L., Marti, J., Basu, S., Cohen, Y. C., Matsumoto, M., Suzuki, K., Hulin, C., Grosicki, S., Legiec, W., Maiolino, A., Ngo, M., Krevvata, M., Rowe, M., Hungria, V. (2025). Daratumumab + bortezomib, lenalidomide, and dexamethasone (DVRd) vs VRd in transplant-ineligible (TIE)/transplant-deferred (TD) newly diagnosed multiple myeloma (NDMM): Phase 3 CEPHEUS trial cytogenetic subgroup analysis.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.7529